✨ Free AI Report
Repare Therapeutics Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Repare Therapeutics Inc.
Company Research

Repare Therapeutics Inc.: Business Overview, Financials & Competitive Analysis

Repare Therapeutics is a clinical-stage precision oncology company that uses its proprietary SNIPRx platform to discover and develop cancer therapies targeting genomic instability and DNA damage repair mechanisms. The...

Analyst-debate audio for Repare Therapeutics Inc.

AskCyborg analysts argue the bull and bear cases for Repare Therapeutics Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
5/ 10Mixed

Cyborg Score thesis

Synthetic lethality-focused precision oncology platform with strong partnerships but facing acquisition transition and clinical...

Read the full analyst-debate transcript →
Industry Clinical-Stage Precision Oncology / Biotechnology
2 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Repare Therapeutics Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Repare Therapeutics Inc. Overview

Pro stress-test →

Repare Therapeutics is a clinical-stage precision oncology company that uses its proprietary SNIPRx platform to discover and develop cancer therapies targeting genomic instability and DNA damage repair mechanisms. The company has strategic collaborations with major pharmaceutical partners including Roche, Bristol-Myers Squibb, and Ono Pharmaceutical.

Strategic Profile

Pro stress-test →

As of January 16, 2026, Repare shareholders approved a plan of arrangement to be acquired by XenoTherapeutics with 99.76% of votes cast in favor. The company has monetized its portfolio through major licensing deals, including a worldwide agreement with Debiopharm for lunresertib worth up to $257 million in milestones, and out-licensed its discovery platforms to DCx Biotherapeutics receiving $1 million upfront and a 9.99% equity stake.

Competitive Landscape

Pro stress-test →

Repare competes in the precision oncology space alongside companies developing synthetic lethal therapeutics and DNA damage repair inhibitors. Strategic partnerships with Roche, Bristol-Myers Squibb, Debiopharm, and academic institutions position Repare within an established biopharma ecosystem rather than as a direct competitor. The acquisition by XenoTherapeutics repositions the company within a non-profit research model.

Industry Context

Repare Therapeutics Inc. operates in Clinical-Stage Precision Oncology / Biotechnology.

Key facts

Founded: 2016 · Headquarters: Montreal, Canada · Employees: ~91 · Revenue: N/A · Market cap: $114.2M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Repare Therapeutics Inc..

  • Pipeline includes multiple clinical programs: RP-1664 (Phase 1 PLK4 inhibitor), RP-3467 (Polθ inhibitor), camonsertib/RP-3500 (ATR inhibitor Phase 1/2), and lunresertib/RP-6306 (PKMYT1 inhibitor Phase 1/2).
  • Major deal with Debiopharm for lunresertib represents $257M+ in potential milestone payments plus royalties.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Shareholders approved XenoTherapeutics acquisition with 99.76% vote; company now operating as subsidiary
  • November 2025Entered definitive agreement for acquisition by XenoTherapeutics at $1.82 per share plus contingent value rights
  • +2 moreTrack every material event for Repare Therapeutics Inc. as it happens. Explore monitoring →
Get alerted when Repare Therapeutics Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

PARP Inhibitors and DNA Repair TherapeuticsEstablished DNA damage repair cancer therapies in clinical use→Synthetic Lethal Drug Discovery PlatformsCompeting platform-based precision oncology approaches→

Compare Repare Therapeutics Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Repare Therapeutics Inc. operates in Clinical-Stage Precision Oncology / Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-Stage Precision Oncology / Biotechnology research →
NEW · MCP server

Ask your AI assistant about Repare Therapeutics Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Repare Therapeutics Inc. and its top competitor on Cyborg Score”
“What did Repare Therapeutics Inc. do this quarter?”
“Is Repare Therapeutics Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Repare Therapeutics Inc. do?+
Repare Therapeutics is a clinical-stage precision oncology company that uses its proprietary SNIPRx platform to discover and develop cancer therapies targeting genomic instability and DNA damage repair mechanisms. The...
What is Repare Therapeutics Inc.'s Cyborg Score?+
Repare Therapeutics Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Repare Therapeutics Inc.'s main competitors?+
Named competitors include PARP Inhibitors and DNA Repair Therapeutics, Synthetic Lethal Drug Discovery Platforms. The full competitive landscape is in the AskCyborg report.
How can I get the full Repare Therapeutics Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Repare Therapeutics Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Repare Therapeutics Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.